Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Esophageal cancers].

A Adenis1, P Catala, X Mirabel

  • 1Département de cancérologie digestive et urologique, Centre Oscar-Lambret, rue Frédéric-Combemale, 59020 Lille Cedex. a-adenis@o-lambret.fr

Bulletin Du Cancer
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.

ESMO open·2025
Same author

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Radiotherapy and skin cancers - An essential collaboration for onco-dermatology.

Annales de dermatologie et de venereologie·2025
Same author

Tackling a worrisome rate of lost to follow-up among migrants with hepatitis B in French Guiana.

Infectious diseases now·2024
Same author

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Multicriteria optimization of radiation therapy: Towards empowerment and standardization of reverse planning for head and neck squamous cell carcinoma.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Esophageal cancer incidence is high in France, with alcohol and tobacco as key risk factors. Current treatments offer limited survival benefits, highlighting the need for improved therapeutic strategies.

Area of Science:

  • Oncology
  • Gastroenterology
  • Public Health

Context:

  • Esophageal cancer incidence remains high in France and other European regions, particularly Brittany, Northern France, and Normandy.
  • Alcohol and tobacco consumption are identified as primary risk factors for esophageal cancer in Western populations.
  • Diagnosis is typically confirmed via upper gastrointestinal endoscopy with biopsies.

Purpose:

  • To review current therapeutic options for esophageal cancer, including surgery and radiochemotherapy.
  • To assess the effectiveness of adjuvant treatments and pre-operative approaches in improving patient survival rates.
  • To emphasize the importance of managing dysphagia in all stages of esophageal cancer.

Summary:

  • Surgery and definitive radiochemotherapy are primary curative treatments, though surgery is more common.

Related Experiment Videos

  • Five-year survival rates after treatment remain low, around 20% in population-based studies.
  • Adjuvant treatments post-surgery have not improved survival, while pre-operative radiochemotherapy shows experimental promise for relapse-free survival.

    • Impact:

    • Current treatment strategies offer limited long-term survival benefits for esophageal cancer patients.
    • The findings underscore the need for further research into more effective adjuvant and pre-operative therapies.
    • Effective symptomatic management of dysphagia is crucial for patient quality of life.